# Phase 1/2 recurrence trials recruiting: 119 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 119 trials in phase 1/2 for recurrence that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 recurrence trials: 119 rows for $5.95, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 3 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/recurrence

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 119
- Recruiting or not yet: 119
- Read on: November 19, 2026

## Trials

The 25 newest of 119, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 16, 2026 | NCT07939971 | A Study of TBS-2025 Monotherapy in Participants With r/r NPM1mut AML | TuHURA Biosciences, Inc. | Phase 1/2 | Not yet recruiting | Acute Myeloid Leukemia | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07939971) |
| November 16, 2026 | NCT07937410 | Chronic Subdural Hematoma Recurrence | Carilion Clinic | Phase 1/2 | Recruiting | Chronic Subdural Hematoma, Recurrent | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07937410) |
| November 12, 2026 | NCT07932496 | A Modular, Phase I/II Study to Evaluate CT204V-CD19 x CD20 in Participants With Relapsed or Refractory B-Cell Malignancies. | AstraZeneca | Phase 1/2 | Not yet recruiting | Relapsed or Refractory B-Cell Malignancies | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07932496) |
| November 2, 2026 | NCT07909031 | CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors | Crescent Biopharma, Inc. | Phase 1/2 | Recruiting | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ, Biliary Tract Cancer (BTC)... | 219 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909031) |
| October 27, 2026 | NCT07899632 | A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors | Medsyn Biopharma, LLC | Phase 1/2 | Not yet recruiting | Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer... | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899632) |
| October 22, 2026 | NCT07890025 | CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II Study | Hospital Universitario Dr. Jose E. Gonzalez | Phase 1/2 | Not yet recruiting | Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890025) |
| October 13, 2026 | NCT07871877 | Medically Supervised Ibogaine With 12-Month Digital Recovery Support for Opioid Use Disorder | Sponsor not shown (see the record) | Phase 1/2 | Not yet recruiting | Opioid Use Disorder, Opioid Withdrawal, Substance Use Disorders | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871877) |
| October 5, 2026 | NCT07859059 | Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma | University of Nebraska | Phase 1/2 | Not yet recruiting | High Grade Glioma, Glioblastoma, Gliosarcoma | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07859059) |
| September 29, 2026 | NCT07847957 | Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL | Dana-Farber Cancer Institute | Phase 1/2 | Not yet recruiting | Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07847957) |
| August 26, 2026 | NCT07788118 | A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 1/2 | Recruiting | Relapsed/Refractory Large B-cell Lymphoma (LBCL), Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large... | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07788118) |
| August 18, 2026 | NCT07770698 | A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia | BeOne Medicines | Phase 1/2 | Not yet recruiting | Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, Pediatric... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07770698) |
| August 4, 2026 | NCT07744256 | Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) | Beijing Biotech | Phase 1/2 | Recruiting | Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC, Extensive-stage SCLC | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07744256) |
| July 28, 2026 | NCT07730125 | Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies | CoRegen, Inc. | Phase 1/2 | Not yet recruiting | HR-positive, HER2-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Prostate Cancer | 67 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07730125) |
| July 23, 2026 | NCT07723482 | ML-016 in Advanced Cancer With Lung and/or Liver Involvement | BrYet US, Inc. | Phase 1/2 | Recruiting | Advanced Solid Tumor With Lung and/or Liver Involvement | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07723482) |
| July 23, 2026 | NCT07722312 | S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory... | Servier | Phase 1/2 | Not yet recruiting | Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Myeloid Leukemia | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07722312) |
| July 17, 2026 | NCT07712562 | A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure Syndromes | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Bone Marrow Failure Syndromes, Aplastic Anemias, Severe Aplastic Anemia (SAA), Severe Aplastic Anemia, Relapse, Severe... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07712562) |
| July 2, 2026 | NCT07681596 | A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma | AstraZeneca | Phase 1/2 | Recruiting | Relapsed or Refractory Multiple Myeloma | 101 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07681596) |
| June 23, 2026 | NCT07662720 | A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer | Glycyx Therapeutics | Phase 1/2 | Not yet recruiting | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07662720) |
| June 3, 2026 | NCT07622940 | Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma | Beijing Biotech | Phase 1/2 | Recruiting | Recurrent or Metastatic Esophageal Adenocarcinoma, Biomarker-selected CLDN18.2-positive and/or HER2-positive Disease | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07622940) |
| June 1, 2026 | NCT07617805 | EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC | Beijing Biotech | Phase 1/2 | Recruiting | Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Biomarker-positive EGFR/HER2- Expressing HNSCC | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07617805) |
| June 1, 2026 | NCT07617753 | Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2 | Beijing Biotech | Phase 1/2 | Recruiting | Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma, Recurrent or Refractory Disease... | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07617753) |
| May 29, 2026 | NCT07615283 | Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma | Sun Yat-sen University | Phase 1/2 | Not yet recruiting | Relapsed or Refractory Peripheral T Cell Lymphoma, NKTCL | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07615283) |
| May 29, 2026 | NCT07612787 | A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma | Centre Hospitalier Universitaire de Saint Etienne | Phase 1/2 | Not yet recruiting | Myeloma Multiple | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07612787) |
| May 27, 2026 | NCT07607925 | A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL | GlaxoSmithKline | Phase 1/2 | Recruiting | Lymphoma, Non-Hodgkin | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07607925) |
| May 22, 2026 | NCT07601607 | Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma | Sun Yat-sen University | Phase 1/2 | Not yet recruiting | Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07601607) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Beijing Biotech](https://specstream.ai/data/clinical-trials/company/beijing-biotech) | 8 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 4 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 4 |
| Princess Maxima Center for Pediatric Oncology | 4 |
| Sun Yat-sen University | 3 |
| Chinese PLA General Hospital | 3 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 3 |
| [ModernaTX, Inc.](https://specstream.ai/data/clinical-trials/company/modernatx-inc) | 2 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 2 |
| National Cancer Institute (NCI) | 2 |
| [Suzhou Suncadia Biopharmaceuticals Co., Ltd.](https://specstream.ai/data/clinical-trials/company/suzhou-suncadia-biopharmaceuticals-co-ltd) | 2 |
| [BeOne Medicines](https://specstream.ai/data/clinical-trials/company/beone-medicines) | 2 |
| Institute of Hematology & Blood Diseases Hospital, China | 2 |
| Dana-Farber Cancer Institute | 2 |
| Genfleet Therapeutics (Shanghai) Inc. | 1 |
| TuHURA Biosciences, Inc. | 1 |
| Centre Hospitalier Universitaire de Saint Etienne | 1 |
| M.D. Anderson Cancer Center | 1 |
| University of Nebraska | 1 |
| Seqker Biosciences, Inc. | 1 |
| Haukeland University Hospital | 1 |
| Servier | 1 |
| Université de Sherbrooke | 1 |
| [Chengdu Zenitar Biomedical Technology Co., Ltd](https://specstream.ai/data/clinical-trials/company/chengdu-zenitar-biomedical-technology-co-ltd) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 46 |
| China | 45 |
| Spain | 18 |
| Australia | 16 |
| Germany | 15 |
| France | 14 |
| Italy | 13 |
| United Kingdom | 10 |
| Japan | 8 |
| South Korea | 8 |
| Poland | 7 |
| Belgium | 7 |
| Taiwan | 7 |
| Canada | 6 |
| Norway | 5 |
| Brazil | 5 |
| Denmark | 5 |
| Israel | 5 |
| Netherlands | 5 |
| Finland | 4 |
| Ireland | 4 |
| Sweden | 4 |
| Austria | 3 |
| Hungary | 2 |
| Switzerland | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Oral and maxillofacial surgery practices in the United States](https://specstream.ai/data/businesses/oral-and-maxillofacial-surgery-practices/united-states)
- [Shared office spaces in the United States](https://specstream.ai/data/businesses/shared-office-spaces/united-states)
- [Window suppliers in the United States](https://specstream.ai/data/businesses/window-suppliers/united-states)
- [Builders in the United States](https://specstream.ai/data/businesses/builders/united-states)
- [Electronic equipment suppliers in the United States](https://specstream.ai/data/businesses/electronic-equipment-suppliers/united-states)
- [Hydro jetting companies in the United States](https://specstream.ai/data/businesses/hydro-jetting-companies/united-states)
